Navigation Links
National Parkinson Foundation Awards More Than $1 Million for Research

MIAMI, June 30, 2011 /PRNewswire-USNewswire/ -- The National Parkinson Foundation (NPF) has awarded more than $1 million dollars in clinical research projects in 2011. Through NPF's individual investigators awards program, NPF is supporting work to advance three key areas of Parkinson's disease (PD): 1) an advanced biomarker study, 2) a clinical trial to treat memory impairment, and 3) a study of the effectiveness of a treatment for sleep apnea in PD.

"Each of these projects can have an immediate impact on the lives of Parkinson's disease patients, from a novel approach to developing a new biomarker to treatments for two important non-motor symptoms," said Joyce Oberdorf, NPF's President and CEO. "Both sleep issues and cognition are important, but often overlooked, contributors to the burden of the disease."

Under the direction of the Clinical and Scientific Advisory Board (CSAB), NPF supports leading-edge research conducted by the top neurological experts at its 43 Centers of Excellence worldwide. These research awards will support three novel clinical investigations at Centers of Excellence in the United States and Canada.

NPF funded the following two-year clinical research grants:

1. MRI Biomarkers for Motor and Non-Motor Manifestations of Parkinson's Disease:  Martin McKeown, MD, and Silke Cresswell, MD, Pacific Parkinson's Research Center, University of British Columbia.
This study will examine Parkinson's disease patients to measure the shapes of deep structures in the brain; the goal is to develop a biomarker for Parkinson's. This new technique combines advances in computing power with established (and inexpensive) imaging techniques to provide greater insight. Drs. McKeown and Cresswell hope to develop a reliable method to assess overall disease severity and this sophisticated technique could be replicated at hospitals anywhere.  

2. Sleep Disordered Breathing and its Impact on Cognitive Performance and Quality of Life in Parkinson's Disease: Carlos Singer, MD, Miller School of Medicine, University of Miami.
Poor sleep affects the quality of life for people with PD, but there is also evidence that it may also contribute to decreased cognition. This study will evaluate the prevalence of sleep disordered breathing (SDB) and test the effectiveness of a common SDB treatment in people with Parkinson's.  Sleep disturbance in PD has been highlighted as not only having a measurable impact on quality of life, but also contributing to trauma and injury associated with reduced vigilance due to fatigue.

3. Sleep and Learn with Transcranial Magnetic Stimulation (TMS) in Parkinson's Disease, M. Felice Ghilardi, MD, New York University Medical School.
Motor learning involves practicing a task followed by forming a habit—a short-cut in the brain to do a complex motion. This study will investigate this process and how it is affected by PD. Dr. Ghilardi will study motor learning in people with PD and then attempt to improve motor learning by stimulating neurons using TMS.  TMS therapy has been shown to activate neurons in the brain and can be targeted to those associated with motor learning. If this technique works, it could be applied to reinforce important motor tasks associated with falls prevention, for example.

For more information on the research conducted at NPF's Centers of Excellence, please visit

About Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's with an estimated one million people with the disease in the United States and four to six million worldwide. There is no cure for Parkinson's disease and 50-60,000 new cases are diagnosed each year in the United States.

About the National Parkinson Foundation
The National Parkinson Foundation supports a strong network of 43 Centers of Excellence dedicated to excellence in research and providing comprehensive, interdisciplinary care to more than 50,000 Parkinson's patients and their families worldwide. Founded in 1957, the National Parkinson Foundation's mission is to improve the quality of care for people with Parkinson's disease through research, education, and outreach. Since 1982, NPF has funded more than $155 million in care, research and support services.

For more information about Parkinson's disease or the National Parkinson Foundation, please visit or call 1-800-4PD-INFO (473-4636).

SOURCE National Parkinson Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Announces Second Quarter Results
7. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
8. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
9. BioMarin Announces Roll-Out of National PKU Registry
10. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
11. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):